B. G. Feagan, W. J. Sandborn, and C. Gasink, Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease, N Engl J Med, vol.375, pp.1946-1960, 2016.

P. Wils, Y. Bouhnik, and P. Michetti, Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience, Aliment Pharmacol Ther, vol.47, pp.588-595, 2018.

C. Ma, R. N. Fedorak, and G. G. Kaplan, Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Realworld Experience from a Multicenter Cohort Study, Inflamm Bowel Dis, vol.23, pp.833-839, 2017.

C. Ma, R. N. Fedorak, and G. G. Kaplan, Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort, Aliment Pharmacol Ther, vol.45, pp.1232-1243, 2017.

X. Roblin, M. Rinaudo, D. Tedesco, and E. , Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases, Am J Gastroenterol, vol.109, pp.1250-1256, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01688079

J. Torres, S. Bonovas, and G. Doherty, ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment, J Crohn's Colitis, vol.1, pp.4-22, 2020.

J. Salleron, S. Danese, D. 'agay, L. , P. et al., Effectiveness Research in Inflammatory Bowel Disease: A Necessity and a Methodological Challenge, J Crohns Colitis, vol.10, pp.1096-102, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01662135

T. Chateau and L. Peyrin-biroulet, Two Cases of Inflammatory Bowel Disease Patients Treated With Ustekinumab 90 mg Every 3 Weeks, Inflamm Bowel Dis, vol.26, p.7, 2020.

J. E. Ollech, I. Normatov, and N. Peleg, Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease, Clin Gastroenterol Hepatol, issue.20, pp.30205-30211, 2020.

V. Biemans, A. E. Van-der-meulen-de-jong, and C. J. Van-der-woude, Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study, J Crohns Colitis, vol.14, pp.33-45, 2020.

S. Vermeire, E. Dreesen, K. Papamichael, and M. C. Dubinsky, How, When, and for Whom Should We Perform Therapeutic Drug Monitoring?, Clin Gastroenterol Hepatol, issue.19, pp.31092-31096, 2019.

J. D. Feuerstein, G. C. Nguyen, and S. S. Kupfer, American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease, Gastroenterology, vol.153, pp.827-834, 2017.

M. P. Sparrow, K. Papamichael, and M. G. Ward, Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response, J Crohns Colitis, p.162, 2019.

O. J. Adedokun, Z. Xu, and C. Gasink, Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease, Gastroenterology, vol.154, pp.1660-1671, 2018.

B. Verstockt, E. Dreesen, and M. Noman, Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates, J Crohns Colitis, vol.13, pp.864-872, 2019.

R. Battat, U. Kopylov, and T. Bessissow, Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease, Clin Gastroenterol Hepatol, vol.15, pp.1427-1434, 2017.